IMTX
$9.83
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.
Recent News
Immatics Phase 3 Progress Sharpens View On Anzu Cel Launch Upside
Immatics (NasdaqCM:IMTX) reported strong enrollment in its Phase 3 SUPRAME trial for anzu-cel (IMA203), its lead cancer immunotherapy candidate. The company has set timelines for the final analysis of the trial and is targeting a future product launch following completion. This update outlines the next key clinical and regulatory steps for Immatics' late stage oncology pipeline. Immatics focuses on T cell based cancer therapies, with anzu-cel at the center of its late stage efforts. For you...
Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate
Immatics N.V. (NASDAQ:IMTX) is among the best German stocks to buy according to analysts. On March 5, Immatics N.V. (NASDAQ:IMTX) reported its financial results for the year ended December 31. It also provided updates on its business. On the financial part, the company reported revenue of $56.8 million, compared to revenue of $183.1 million in […]
Immatics: Q4 Earnings Snapshot
TUBINGEN, Germany (AP) — Immatics N.V. (IMTX) on Thursday reported a loss of $41.6 million in its fourth quarter. The Tubingen, Germany-based company said it had a loss of 34 cents per share. The company posted revenue of $23 million in the period.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -650.00% and +5.42%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Institutional investors own a significant stake of 38% in Immatics N.V. (NASDAQ:IMTX)
Key Insights Significantly high institutional ownership implies Immatics' stock price is sensitive to their trading...